The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The Search for a Better Treatment for Recurrent Clostridium difficile Disease: Use of High‐Dose Vancomycin Combined with Saccharomyces boulardii
Abstract
Recurrent Clostridium difficile disease (CDD) is a difficult clinical problem because antibiotic therapy often does not prevent further recurrences. In a previous study, the biotherapeutic agent Saccharomyces boulardii was used in combination with standard antibiotics and was found to be effective in reducing subsequent recurrences of CDD. In an effort to further refine a standard regimen, we tested patients receiving a regimen of a standard antibiotic for 10 days and then added either S. boulardii (1 g/day for 28 days) or placebo. A significant decrease in recurrences was observed only in patients treated with high-dose vancomycin (2 g/day) and S. boulardii (16.7%), compared with those who received high-dose vancomycin and placebo (50%; P=.05). No serious adverse reactions were observed in these patients. Comparison of data from this trial with data from previous studies indicates that recurrent CDD may respond to a short course of high-dose vancomycin or to longer courses of low-dose vancomycin when either is combined with S. boulardii.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McFarland, L. V. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510480037031 · Cited by 857
Self-citation(1995) · American Journal of Infection Control · doi:10.1016/0196-6553(95)90104-3 · Cited by 709
Clostridium Difficile-Associated Diarrhea and Colitis
Gerding, D. N., Johnson, S., Peterson, L. R., Mulligan, M. E., & Silva, J. (1995) · Infection Control & Hospital Epidemiology · doi:10.1086/648363 · Cited by 631
Self-citationPrevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study
Surawicz, C. M., Elmer, G. W., Speelman, P., McFarland, L. V., Chinn, J., & Van Belle, G. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)91613-2 · Cited by 573
Self-citationWenisch, C., Parschalk, B., Hasenhundl, M., Hirschl, A. M., & Graninger, W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.5.813 · Cited by 505
Fekety, R. (1997) · PubMed · Cited by 442
Self-citationCastagliuolo, I., Riegler, M. F., Valenick, L., LaMont, J. T., & Pothoulakis, C. (1999) · Infection and Immunity · doi:10.1128/iai.67.1.302-307.1999 · Cited by 408
Clostridium difficile-Associated Diarrhea and Colitis
Gerding, D. N., Johnson, S., Peterson, L. R., Mulligan, M. E., & Silva, J. (1995) · Infection Control and Hospital Epidemiology · doi:10.2307/30141083 · Cited by 398
Self-citationFekety, R., McFarland, L. V., Surawicz, C. M., Greenberg, R. N., Elmer, G. W., & Mulligan, M. E. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.3.324 · Cited by 376
Self-citationRecurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics
McFarland, L. V., Surawicz, C. M., Rubin, M., Fekety, R., Elmer, G. W., & Greenberg, R. N. (1999) · Infection Control & Hospital Epidemiology · doi:10.1086/501553 · Cited by 353
Self-citation
Cited by
Gut microbiota in health and disease
Sekirov, I., Russell, S. L., Antunes, L. C. M., & Finlay, B. B. (2010) · Physiological Reviews · doi:10.1152/physrev.00045.2009 · Cited by 4,182
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
Gough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003
Treating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003
Self-citationPotential Uses of Probiotics in Clinical Practice
Reid, G., Jass, J., Sebulsky, M. T., & McCormick, J. K. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.4.658-672.2003 · Cited by 912
Health Care Costs and Mortality Associated with Nosocomial Diarrhea Due to Clostridium difficile
Kyne, L., Hamel, M. B., Polavaram, R., & Kelly, C. P. (2002) · Clinical Infectious Diseases · doi:10.1086/338260 · Cited by 904
McFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872
“Of the three different probiotics tested for the treatment of CDD, only S. boulardii showed significant reductions in recurrences of CDD (57, 58 ).”
BackgroundInfluentialSelf-citationBreaking The Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium Difficile Disease
McFarland, L. V., Elmer, G. W., & Surawicz, C. M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05839.x · Cited by 724
Self-citationKelly, C. R., Khoruts, A., Staley, C., Sadowsky, M. J., Abd, M., Alani, M., Bakow, B., Curran, P., McKenney, J., Tisch, A., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0271 · Cited by 613
Narrative Review: The New Epidemic of Clostridium difficile–Associated Enteric Disease
Bartlett, J. G. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00008 · Cited by 599
Review article: yeast as probiotics – Saccharomyces boulardii
CZERUCKA, D., PICHE, T., & RAMPAL, P. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03442.x · Cited by 587
ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections
Kelly, C. R., Fischer, M., Allegretti, J. R., LaPlante, K., Stewart, D. B., Limketkai, B. N., & Stollman, N. H. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001278 · Cited by 579
Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C. (2005) · Clinical Infectious Diseases · doi:10.1086/430315 · Cited by 570
Sazawal, S., Hiremath, G., Dhingra, U., Malik, P., Deb, S., & Black, R. E. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70495-9 · Cited by 561
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients
McFarland, L. V. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i18.2202 · Cited by 545
Self-citationGut microbiota: a potential new territory for drug targeting
Jia, W., Li, H., Zhao, L., & Nicholson, J. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2505 · Cited by 475
Clostridium difficile-associated diarrhea in adults
Poutanen, S. M. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031189 · Cited by 410
Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
Johnson, S. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.03.010 · Cited by 397
Kelesidis, T., & Pothoulakis, C. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11428502 · Cited by 377
Mattila, E., Uusitalo–Seppälä, R., Wuorela, M., Lehtola, L., Nurmi, H., Ristikankare, M., Moilanen, V., Salminen, K., Seppälä, M., Mattila, P. S., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.037 · Cited by 371
Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review
Drekonja, D., Reich, J., Gezahegn, S., Greer, N., Shaukat, A., MacDonald, R., Rutks, I., & Wilt, T. J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2693 · Cited by 371
Bauer, M. P., Kuijper, E. J., & van Dissel, J. T. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03099.x · Cited by 366
Probiotics for Prevention and Treatment of Diarrhea
Guandalini, S. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182257e98 · Cited by 346
Antimicrobial and Probiotic Properties of Yeasts: From Fundamental to Novel Applications
Hatoum, R., Labrie, S., & Fliss, I. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00421 · Cited by 338
Senok, A. C., Ismaeel, A. Y., & Botta, G. A. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01228.x · Cited by 327
PASSCLAIM1?Gut health and immunity
Cummings, J. H., Antoine, J.-M., Azpiroz, F., Bourdet-Sicard, R., Brandtzaeg, P., Calder, P. C., Gibson, G. R., Guarner, F., Isolauri, E., Pannemans, D., et al. (2004) · European Journal of Nutrition · doi:10.1007/s00394-004-1205-4 · Cited by 324
Khanna, S., Pardi, D. S., Kelly, C. R., Kraft, C. S., Dhere, T., Henn, M. R., Lombardo, M.-J., Vulic, M., Ohsumi, T., Winkler, J., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv766 · Cited by 321
Infection control measures to limit the spread of Clostridium difficile
Vonberg, R.-P., Kuijper, E. J., Wilcox, M. H., Barbut, F., Tüll, P., Gastmeier, P., van den Broek, P. J., Colville, A., Coignard, B., Daha, T., et al. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01992.x · Cited by 314
Johnson, S., Schriever, C., Galang, M., Kelly, C. P., & Gerding, D. N. (2007) · Clinical Infectious Diseases · doi:10.1086/511870 · Cited by 312
Tejero-Sariñena, S., Barlow, J., Costabile, A., Gibson, G. R., & Rowland, I. (2012) · Anaerobe · doi:10.1016/j.anaerobe.2012.08.004 · Cited by 296
Treatment of Clostridium difficile Infection
Gerding, D. N., Muto, C. A., & Owens, Jr. (2008) · Clinical Infectious Diseases · doi:10.1086/521860 · Cited by 287
Bacteriotherapy Using Fecal Flora: Toying With Human Motions
Borody, T. J., Warren, E. F., Leis, S. M., Surace, R., Ashman, O., & Siarakas, S. (2004) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000128988.13808.dc · Cited by 283
Protective nutrients and functional foods for the gastrointestinal tract
Duggan, C., Gannon, J., & Walker, W. A. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/75.5.789 · Cited by 276
Clostridium diffcile associated infection, diarrhea andcolitis
Hookman, P., & Barkin, J. S. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1554 · Cited by 275
New Approaches for Bacteriotherapy: Prebiotics, New-Generation Probiotics, and Synbiotics
Patel, R., & DuPont, H. L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ177 · Cited by 267
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide
Sniffen, J. C., McFarland, L. V., Evans, C. T., & Goldstein, E. J. C. (2018) · PLOS ONE · doi:10.1371/journal.pone.0209205 · Cited by 265
Self-citationRegulatory Oversight and Safety of Probiotic Use
Venugopalan, V., Shriner, K. A., & Wong-Beringer, A. (2010) · Emerging Infectious Diseases · doi:10.3201/eid1611.100574 · Cited by 216
Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options
Lo Vecchio, A., & Zacur, G. M. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834bc9a9 · Cited by 183
Probiotic Effects on Inflammatory Bowel Disease1,
Sheil, B., Shanahan, F., & O’Mahony, L. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.3.819s · Cited by 167
Sartelli, M., Di Bella, S., McFarland, L. V., Khanna, S., Furuya-Kanamori, L., Abuzeid, N., Abu-Zidan, F. M., Ansaloni, L., Augustin, G., Bala, M., et al. (2019) · World Journal of Emergency Surgery · doi:10.1186/s13017-019-0228-3 · Cited by 159
Self-citationChoi, C. H., Jo, S. Y., Park, H. J., Chang, S. K., Byeon, J.-S., & Myung, S.-J. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318204593e · Cited by 144
Kaźmierczak-Siedlecka, K., Ruszkowski, J., Fic, M., Folwarski, M., & Makarewicz, W. (2020) · Current Microbiology · doi:10.1007/s00284-020-02053-9 · Cited by 127
Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections
Czerucka, D., & Rampal, P. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i18.2188 · Cited by 116
Kabbani, T. A., Pallav, K., Dowd, S. E., Villafuerte-Galvez, J., Vanga, R. R., Castillo, N. E., Hansen, J., Dennis, M., Leffler, D. A., & Kelly, C. P. (2017) · Gut Microbes · doi:10.1080/19490976.2016.1267890 · Cited by 115
“Moreover, SB may also be beneficial for the prevention of recurrent CDI.(13,16)Some of the described mechanisms of action of SB include interference with bacterial adhesion, inactivation of toxins and other virulence factors, and enhancement of mucosal immune function.”
BackgroundMcFarland, L. (2015) · Antibiotics · doi:10.3390/antibiotics4020160 · Cited by 109
Self-citationSbahi, H., & Di Palma, J. A. (2016) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2016-000087 · Cited by 75
Trubiano, J. A., Gardiner, B., Kwong, J. C., Ward, P., Testro, A. G., & Charles, P. G. P. (2013) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32835b2da9 · Cited by 64
Probiotics Used in Human Studies
Montrose, D. C., & Floch, M. H. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000165649.32371.71 · Cited by 60
Bugs or drugs: Are probiotics safe for use in the critically ill?
Urben, L. M., Wiedmar, J., Boettcher, E., Cavallazzi, R., Martindale, R. G., & McClave, S. A. (2014) · Current Gastroenterology Reports · doi:10.1007/s11894-014-0388-y · Cited by 29
Metadata
- Authors
- Surawicz, C. M., McFarland, L. V., Greenberg, R. N., Rubin, M., Fekety, R., Mulligan, M. E., Garcia, R. J., Brandmarker, S., Bowen, K., Borjal, D., & Elmer, G. W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-10
- Volume
- 31
- Issue
- 4
- Pages
- 1012-1017
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2128175074
- Cited by
- 529
- References
- 28
- FWCI
- 9.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.